Validation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX

医学 叶黄素 胰腺癌 新辅助治疗 肿瘤科 胰腺切除术 内科学 辅助治疗 佐剂 癌症 外科 伊立替康 胰腺 结直肠癌 乳腺癌
作者
Ingmar F. Rompen,Thomas F. Stoop,Stijn van Roessel,Eran van Veldhuisen,Quisette P. Janssen,Adnan Alseidi,Alberto Balduzzi,Gianpaolo Balzano,Frederik Berrevoet,Morgan Bonds,Olivier R. Busch,Giovanni Butturini,Ammar A. Javed,Marco Del Chiaro,Kevin C. Conlon,Massimo Falconi,Isabella Frigerio,Giuseppe Fusai,Johan Gagnière,Oonagh Griffin
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
标识
DOI:10.1097/sla.0000000000006650
摘要

To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of pancreatic ductal adenocarcinoma (PDAC) following neoadjuvant FOLFIRINOX. The PANAMA-score was developed to guide prognostication in patients after neoadjuvant therapy and resection for PDAC. As this score focuses on the risk for residual disease after resection, it might also be able to select patients who benefit from adjuvant after neoadjuvant therapy. This retrospective international multicenter study is endorsed by the European-African Hepato-Pancreato-Biliary Association (E-AHPBA). Patients with PDAC who underwent resection after neoadjuvant FOLFIRINOX were included. Mantel-Cox regression with interaction analysis was performed to assess the impact of adjuvant chemotherapy. Overall, 383 patients after resection of PDAC following neoadjuvant FOLFIRINOX were included of whom 187 (49%), 137 (36%), and 59 (15%) had a low-risk, intermediate-risk, and high-risk PANAMA-score, respectively. A discrimination in median OS was observed stratified by risk groups (48.5, 27.6, and 22.3 months, Log-Rank-Plow-intermediate=0.004, Log-Rank-Pintermediate-high=0.027). Adjuvant therapy was not associated with an OS difference in the low-risk group (HR 1.50, 95%CI:0.92-2.50), whereas improved OS was observed in the intermediate (HR 0.58, 95%CI:0.34-0.97) and high-risk groups (HR 0.47, 95%CI:0.24-0.94) (p-interaction=0.008). The PANAMA 3-tier risk groups (low-risk, intermediate-risk, and high-risk, available via pancreascalculator.com) correspond with differential survival in patients with resected PDAC following neoadjuvant FOLFIRINOX. The risk groups also differentiate between survival benefit associated with adjuvant treatment, with only the intermediate- and high-risk groups associated with improved OS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
情怀应助后陡门58采纳,获得10
刚刚
慕青应助Rrr采纳,获得10
1秒前
1秒前
LC发布了新的文献求助10
1秒前
科研小白完成签到,获得积分10
3秒前
土豆发布了新的文献求助10
3秒前
上官若男应助科研狗采纳,获得10
4秒前
zhh发布了新的文献求助10
4秒前
博儒艾特发布了新的文献求助30
5秒前
木刻青、发布了新的文献求助10
5秒前
5秒前
好好发布了新的文献求助10
6秒前
科研通AI5应助给好评采纳,获得10
6秒前
7秒前
小蘑菇应助北柑采纳,获得10
8秒前
科研通AI5应助MXene采纳,获得10
10秒前
10秒前
10秒前
优秀傲松发布了新的文献求助10
10秒前
10秒前
11秒前
11秒前
12秒前
12秒前
12秒前
内向映天完成签到 ,获得积分10
13秒前
13秒前
涛涛驳回了打打应助
14秒前
科研八戒应助zhh采纳,获得10
14秒前
Ava应助Qinjichao采纳,获得10
15秒前
无花果应助机智的Kiki采纳,获得10
15秒前
16秒前
16秒前
SciGPT应助唐慕晴采纳,获得50
16秒前
17秒前
17秒前
小笼包发布了新的文献求助10
17秒前
18秒前
19秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
Walter Gilbert: Selected Works 500
An Annotated Checklist of Dinosaur Species by Continent 500
岡本唐貴自伝的回想画集 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
彭城银.延安时期中国共产党对外传播研究--以新华社为例[D].2024 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3655029
求助须知:如何正确求助?哪些是违规求助? 3218224
关于积分的说明 9722468
捐赠科研通 2926343
什么是DOI,文献DOI怎么找? 1602734
邀请新用户注册赠送积分活动 755703
科研通“疑难数据库(出版商)”最低求助积分说明 733433